[1]
Nutritional anaemias. Report of a WHO scientific group. World Health Organization technical report series. 1968; [PubMed PMID: 4975372]
[2]
McClellan WM,Flanders WD,Langston RD,Jurkovitz C,Presley R, Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. Journal of the American Society of Nephrology : JASN. 2002 Jul; [PubMed PMID: 12089390]
[3]
Collins AJ,Li S,St Peter W,Ebben J,Roberts T,Ma JZ,Manning W, Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. Journal of the American Society of Nephrology : JASN. 2001 Nov; [PubMed PMID: 11675424]
[4]
Bernhardt WM,Wiesener MS,Scigalla P,Chou J,Schmieder RE,Günzler V,Eckardt KU, Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. Journal of the American Society of Nephrology : JASN. 2010 Dec; [PubMed PMID: 21115615]
[5]
Wang GL,Jiang BH,Rue EA,Semenza GL, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the United States of America. 1995 Jun 6; [PubMed PMID: 7539918]
[6]
Agarwal AK, Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. Journal of the American Medical Directors Association. 2006 Nov; [PubMed PMID: 17098634]
[7]
Hsu CY,McCulloch CE,Curhan GC, Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. Journal of the American Society of Nephrology : JASN. 2002 Feb; [PubMed PMID: 11805181]
[8]
Tessitore N,Solero GP,Lippi G,Bassi A,Faccini GB,Bedogna V,Gammaro L,Brocco G,Restivo G,Bernich P,Lupo A,Maschio G, The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2001 Jul; [PubMed PMID: 11427634]
[9]
Mittman N,Sreedhara R,Mushnick R,Chattopadhyay J,Zelmanovic D,Vaseghi M,Avram MM, Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1997 Dec; [PubMed PMID: 9398141]
[10]
Coyne DW,Kapoian T,Suki W,Singh AK,Moran JE,Dahl NV,Rizkala AR, Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. Journal of the American Society of Nephrology : JASN. 2007 Mar; [PubMed PMID: 17267740]
[11]
Radtke HW,Claussner A,Erbes PM,Scheuermann EH,Schoeppe W,Koch KM, Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. Blood. 1979 Oct; [PubMed PMID: 476305]
[12]
Korte W,Cogliatti SB,Jung K,Riesen W, Mild renal dysfunction is sufficient to induce erythropoietin deficiency in patients with unexplained anaemia. Clinica chimica acta; international journal of clinical chemistry. 2000 Feb 25; [PubMed PMID: 10686284]
[13]
DeGowin RL,Lavender AR,Forland M,Charleston D,Gottschalk A, Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Annals of internal medicine. 1970 Jun; [PubMed PMID: 5448750]
[14]
Richardson JR Jr,Weinstein MB, Erythropoietic response of dialyzed patients to testosterone administration. Annals of internal medicine. 1970 Sep; [PubMed PMID: 5455991]
[15]
Eschbach JW,Egrie JC,Downing MR,Browne JK,Adamson JW, Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. The New England journal of medicine. 1987 Jan 8; [PubMed PMID: 3537801]
[16]
Macdougall IC,Lewis NP,Saunders MJ,Cochlin DL,Davies ME,Hutton RD,Fox KA,Coles GA,Williams JD, Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet (London, England). 1990 Mar 3; [PubMed PMID: 1968526]
[17]
Perkins R,Olson S,Hansen J,Lee J,Stiles K,Lebrun C, Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis. Nephrology nursing journal : journal of the American Nephrology Nurses' Association. 2007 Mar-Apr; [PubMed PMID: 17486947]
[18]
Maddux FW,Shetty S,del Aguila MA,Nelson MA,Murray BM, Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. The Annals of pharmacotherapy. 2007 Nov; [PubMed PMID: 17895328]
[19]
Carrera F,Burnier M, Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT plus. 2009 Jan; [PubMed PMID: 19461859]
[20]
Egrie JC,Browne JK, Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2001; [PubMed PMID: 11402085]
[21]
Winearls CG,Oliver DO,Pippard MJ,Reid C,Downing MR,Cotes PM, Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet (London, England). 1986 Nov 22; [PubMed PMID: 2877323]
[22]
Szczech LA,Barnhart HX,Inrig JK,Reddan DN,Sapp S,Califf RM,Patel UD,Singh AK, Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney international. 2008 Sep; [PubMed PMID: 18596733]
[23]
Besarab A,Bolton WK,Browne JK,Egrie JC,Nissenson AR,Okamoto DM,Schwab SJ,Goodkin DA, The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. The New England journal of medicine. 1998 Aug 27; [PubMed PMID: 9718377]
[24]
Bello NA,Lewis EF,Desai AS,Anand IS,Krum H,McMurray JJ,Olson K,Solomon SD,Swedberg K,van Veldhuisen DJ,Young JB,Pfeffer MA, Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European journal of heart failure. 2015 Nov; [PubMed PMID: 26423928]
[25]
Fishbane S,Berns JS, Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney international. 2005 Sep; [PubMed PMID: 16105069]
[26]
Fudin R,Jaichenko J,Shostak A,Bennett M,Gotloib L, Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron. 1998; [PubMed PMID: 9678430]
[27]
Markowitz GS,Kahn GA,Feingold RE,Coco M,Lynn RI, An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clinical nephrology. 1997 Jul; [PubMed PMID: 9247776]
[28]
Macdougall IC, Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. Clinical kidney journal. 2017 Dec; [PubMed PMID: 29225819]